Last updated: February 24, 2026
What is the drug associated with NDC 00143-1227?
NDC 00143-1227 corresponds to Eliquis (apixaban), an oral anticoagulant medication used primarily to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation and for treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Approved by the FDA in December 2012, Eliquis is branded by Bristol-Myers Squibb and Pfizer.
What is the current market landscape for Eliquis?
Market Size and Growth
-
The global anticoagulant market is projected to grow at a compound annual growth rate (CAGR) of approximately 6% from 2022 to 2027, reaching an estimated valuation of $12.5 billion by 2027 (Grand View Research, 2022).
-
In the U.S., Eliquis held a 52% market share among direct oral anticoagulants (DOACs) in 2022, surpassing competitors such as Pradaxa (dabigatran) and Xarelto (rivaroxaban).
Key Competitors
| Drug |
Market Share (2022) |
Brand |
Approval Year |
Key Indications |
| Eliquis (apixaban) |
52% |
Bristol-Myers Squibb/Pfizer |
2012 |
Atrial fibrillation, DVT, PE |
| Xarelto (rivaroxaban) |
35% |
Janssen |
2011 |
Same as Eliquis |
| Pradaxa (dabigatran) |
8% |
Boehringer Ingelheim |
2010 |
Same as Eliquis |
| Other |
5% |
- |
- |
Rare uses |
Market Drivers
- Increasing prevalence of atrial fibrillation, DVT, PE.
- Physician preference for DOACs over warfarin due to reduced monitoring requirements.
- Expanding indications, including secondary stroke prevention.
Regulatory and Patent Landscape
-
Patent expiration for Eliquis in the U.S. is projected around 2026-2028, with some formulations potentially facing biosimilar competition thereafter.
-
The patent for Eliquis in major markets remains under litigation, influencing potential generic entry post-2026.
What are the price trends and projections?
Current Pricing
-
Wholesale Acquisition Cost (WAC): Approximate price per 60 mg tablet (twice daily dose): $25-$30, translating to roughly $1,500-$2,000/month per patient.
-
Average Retail Price: Slightly higher than WAC, often in the $30 per tablet range.
-
Reimbursement Rates: Payers negotiate significant discounts, leading to effective prices potentially 30-50% lower.
Price Trends (2018–2022)
-
Stable pricing with slight declines commencing in 2020, attributed to increased generic competition in Europe and patent challenges in the U.S.
-
Price erosion projected to accelerate post-2026 with patent expiry and emergence of biosimilars.
Forecasted Price Trajectory (2023–2030)
| Year |
Estimated Average Price (per month) |
Key Factors |
| 2023 |
$1,500 |
Market stabilization |
| 2024 |
$1,450 |
Negotiation leverage by payers |
| 2025 |
$1,400 |
Rising generic competition in Europe |
| 2026 |
$1,200 |
U.S. patent expiry, biosimilar entry anticipated |
| 2027–2030 |
$800–$1,000 |
Increased biosimilar and generic market share |
Influences on Price
- Patent expiration timeline.
- Insurers' coverage policies.
- Manufacturer strategies for pricing and launching biosimilars.
- Regulatory approvals for biosimilars in key markets.
What are the key factors affecting the market and pricing?
- Patent and IP status: Current exclusivity is key to current pricing levels.
- Biosimilar development: Entering the market post-2026 will exert downward pressure.
- Physician and patient acceptance: Influenced by cost, safety, and efficacy data.
- Healthcare policy: Insurers’ formulary preferences can limit access and influence price negotiations.
What are the implications for stakeholders?
- Pharmaceutical companies: Need to navigate patent strategies, biosimilar development, and regulatory pathways.
- Investors: Should monitor patent expiration plans and biosimilar pipelines.
- Healthcare providers: Consider cost-effectiveness alongside clinical efficacy.
- Payers: Focus on negotiating discounts and managing formulary inclusions.
Key Takeaways
- NDC 00143-1227 is Eliquis (apixaban), a leading DOAC with over 50% U.S. market share.
- The market is driven by increasing indications, preference over warfarin, and competitive dynamics.
- Current prices are stable but poised for decline after patent expiry, with substantial drops forecasted post-2026.
- The emergence of biosimilars will likely accelerate price erosion.
- Patent litigation and regulatory pathways are critical to market timelines and pricing strategies.
FAQs
Q1: When is patent expiration for Eliquis in the U.S.?
A1: Patent protections are expected to expire around 2026–2028, with some legal uncertainties possibly influencing this timeline.
Q2: How will biosimilar entry affect Eliquis prices?
A2: Biosimilar competition is expected to reduce prices by 30–50% once they gain regulatory approval and market acceptance.
Q3: Are there alternative therapies that could replace Eliquis?
A3: Yes, other DOACs like rivaroxaban and dabigatran are primary competitors, with warfarin still used where cost is a major factor.
Q4: What is the primary driver for pricing stability or decline?
A4: Patent status and biosimilar development are the main factors influencing pricing trends.
Q5: Which markets are most impacted by Eliquis price changes?
A5: The U.S. remains the most significant market due to pricing and patent protections; Europe also faces similar with generic entry post-patent expiry.
References
[1] Grand View Research. (2022). Anticoagulants Market Size, Share & Trends Analysis.
[2] U.S. Food and Drug Administration. (2012). FDA approves Eliquis to reduce stroke risk.
[3] IQVIA. (2022). National Drug Trends Report.
